ImmunityBio Inc. saw its equity value jump approximately 9% in trading, reaching an intraday high of $8.66, following a significant announcement regarding its manufacturing capabilities. The biotech firm confirmed it has successfully validated the large-scale production and cryopreservation of its autologous M-ceNK cells, marking a pivotal technological achievement.
A Scalability Milestone for Personalized Medicine
The core of today’s news centers on demonstrating scalable production, a historic bottleneck for autologous cell therapies. Data from the NK2022 and NK2023 programs, which involved 74 participants, showed that a single apheresis procedure could yield up to 5 billion NK cells. This output is sufficient to create between 8 and 10 therapeutic doses within a 12-day timeframe.
Crucially, the company’s cryopreservation process maintains the cells’ cytotoxicity against multiple tumor cell lines. Research presented at the 2026 AACR IO Annual Meeting indicated that NK cells derived from cancer patients demonstrated efficacy equivalent to those from healthy donors.
Complementary Clinical Safety Data
In a related development, ImmunityBio released findings from its Phase 1 QUILT-3.076 trial. This study involved ten patients with a range of cancers, including breast, colorectal, pancreatic, and renal cell carcinoma. Participants were treated with a combination of M-ceNK cells and ANKTIVA (nogapendekin alfa inbakicept). The treatment regimen was reported with a favorable safety profile: there were no Grade 4 or 5 treatment-related adverse events and not a single case of cytokine release syndrome.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Strategic Timing for Regulatory and Commercial Goals
This manufacturing progress arrives at a strategically important moment for the company. On March 9, ImmunityBio submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration. The application seeks approval for ANKTIVA in combination with BCG for the treatment of non-muscle invasive bladder cancer.
Financially, the company has shown remarkable growth. Its fiscal year 2025 revenue reached $113 million, representing a staggering 700% increase over the prior year.
The newly validated processes address one of the most significant barriers to the widespread clinical adoption of personalized cell therapies: complex, patient-specific manufacturing. By proving that multiple treatment doses can be generated from a single cell collection, ImmunityBio moves closer to a commercially viable model for delivering these advanced therapies.
Ad
ImmunityBio Stock: Buy or Sell?! New ImmunityBio Analysis from March 14 delivers the answer:
The latest ImmunityBio figures speak for themselves: Urgent action needed for ImmunityBio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 14.
ImmunityBio: Buy or sell? Read more here...
